Genzyme, Biogen Idec Stocks Mixed on Icahn News
Robert Buderi11/15/07
Shares of Massachusetts’ two leading biotechs, Genzyme and Biogen Idec, showed a mixed response to last night’s news from SEC filings that activist investor Carl Icahn was showing increased interest in the firms. Biogen, where Icahn almost tripled his previous stake, to 8.8 millon shares, fell $0.09, to $69.92. Genzyme, where Icahn took a new stake of nearly 1 percent, rose $2.08 (nearly 3 percent), to $72.84.
Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.
